Evaluates DR5 signaling antagonism in murine cells, suggesting potential for liver disease therapies.
values for antagonism of TRAIL-induced DR5 signaling, measured via caspase 8 activation, in both murine and human cells, albeit with incomplete inhibition. This engineered affibody provides a promising candidate for therapeutic development targeting DR5-mediated liver disease. Further functional characterization and pharmacokinetic optimization are required to advance these findings toward preclinical evaluation in murine MASH models and, ultimately, clinical applications.
No takes yet. Share an insight, caveat, or question.
Kuo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: